Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine

作者：Emma Rubenstein, Myriam Diemer, Lauriane Goldwirt, Caroline Lascoux‐Combe, Marie‐Laure Chaix, Agathe Rami, Diane Ponscarme, Matthieu Lafaurie, Blandine Denis, Nathalie De Castro, Julien Gras, Geoffroy Liégeon, Pierre‐Olivier Sellier, Laure Deville, Sylvie Chevret, Constance Delaugerre, Jean‐Michel Molina · 发表于：AIDS · 年份：2024 · DOI：10.1097/qad.0000000000003887 · 被引用次数：12 · 研究领域：HIV/AIDS drug development and treatment、HIV Research and Treatment、Pneumocystis jirovecii pneumonia detection and treatment

In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7-29.5], P = 0.01] and three months (OR = 5.6 [95% CI 1.3-29.7], P = 0.03), and with high BMI at 1 month (OR = 1.3 [95% CI 1.1-1.6], P = 0.007).